Deferasirox Supply Across LATAM
DEFRATAJ — WHO-GMP Deferasirox dispersible tablets, supplied direct from the manufacturer.
Supply & Market
Latin America represents a sophisticated, institutionally organised pharmaceutical market with a meaningful burden of thalassemia, sickle-cell disease and myelodysplastic syndromes - driving demand for oral iron chelation. Taj Pharma supplies DEFRATAJ Deferasirox dispersible tablets into LATAM through qualified distributor partners and public-sector tender programmes.
Safety-stock blocks of DEFRATAJ in the most-requested strengths are held for sample dispatch and bridging supply. Full PO quantities are released against agreed production lead times, with weekly status reporting. Logistics options include FOB Mumbai / Nhava Sheva / Mundra, CIF major LATAM ports (Santos, Callao, Buenos Aires, Cartagena, Veracruz), and DDP via experienced freight partners. Multilingual artwork (Spanish, Portuguese) and country-specific GTIN coding are supported. Currency options include USD and EUR.
Our regulatory team supplies Module 1-5 CTD dossiers aligned to LATAM regulators including ANVISA (Brazil), COFEPRIS (Mexico), INVIMA (Colombia), DIGEMID (Peru), ANMAT (Argentina), ISP (Chile) and others. LATAM assessment typically requires comprehensive bioequivalence data and detailed Module 3 quality package - both available. Country-specific Module 1 localisation in Portuguese (Brazil) and Spanish (Spanish-speaking markets) is supported. Registration timelines range 12-30 months depending on pathway and authority. CDA-protected dossier sharing typically completes within five working days of NDA execution.